The Chemours Company (NYSE:CC) Receives Consensus Rating of “Hold” from Analysts

The Chemours Company (NYSE:CC) has been assigned an average rating of “Hold” from the nine ratings firms that are presently covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $24.11.

Several research analysts have recently issued reports on CC shares. Barclays boosted their price objective on shares of Chemours from $21.00 to $23.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Mizuho reduced their price objective on Chemours from $22.00 to $21.00 and set a “neutral” rating for the company in a research report on Tuesday, January 7th. BMO Capital Markets boosted their price objective on Chemours from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, October 7th. Morgan Stanley reduced their target price on Chemours from $25.00 to $22.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, The Goldman Sachs Group lowered their price target on shares of Chemours from $24.00 to $21.00 and set a “neutral” rating on the stock in a report on Tuesday, January 7th.

Chemours Trading Up 1.1 %

Chemours stock opened at $18.97 on Thursday. The business’s 50-day simple moving average is $19.17 and its 200-day simple moving average is $19.55. Chemours has a 52 week low of $15.10 and a 52 week high of $31.76. The firm has a market capitalization of $2.83 billion, a PE ratio of 37.93 and a beta of 1.83. The company has a debt-to-equity ratio of 6.05, a quick ratio of 0.92 and a current ratio of 1.73.

Chemours (NYSE:CC) last posted its quarterly earnings data on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.08. Chemours had a return on equity of 29.48% and a net margin of 1.34%. The company had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.44 billion. During the same period in the prior year, the business earned $0.64 earnings per share. Chemours’s revenue for the quarter was up .9% compared to the same quarter last year. Equities research analysts forecast that Chemours will post 1.19 earnings per share for the current year.

Insider Transactions at Chemours

In other news, SVP Alvenia Scarborough sold 7,500 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $20.64, for a total value of $154,800.00. Following the completion of the sale, the senior vice president now directly owns 16,645 shares in the company, valued at approximately $343,552.80. This trade represents a 31.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.47% of the company’s stock.

Hedge Funds Weigh In On Chemours

Institutional investors have recently modified their holdings of the stock. Blue Trust Inc. increased its holdings in shares of Chemours by 166.9% in the third quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company’s stock valued at $26,000 after purchasing an additional 731 shares in the last quarter. Matrix Trust Co acquired a new stake in shares of Chemours in the 3rd quarter valued at $25,000. GAMMA Investing LLC lifted its stake in shares of Chemours by 99.7% during the fourth quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company’s stock valued at $26,000 after acquiring an additional 765 shares during the period. Truvestments Capital LLC bought a new position in Chemours in the third quarter valued at about $35,000. Finally, Brooklyn Investment Group acquired a new stake in Chemours in the third quarter worth about $37,000. 76.26% of the stock is owned by institutional investors.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.